VanEck Pharmaceutical ETF (PPH) Annual Income Statement (USD)
PPH Quarterly Financials (USD)
Frequently Asked Questions About VanEck Pharmaceutical ETF (PPH) Stock
VanEck Pharmaceutical ETF's (PPH) last reported annual revenue was USD 127.47 Million.
VanEck Pharmaceutical ETF's (PPH) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
VanEck Pharmaceutical ETF's(PPH) is profitable as of its last reported annual financials.
The net profit margin for VanEck Pharmaceutical ETF's(PPH) from its laster reported year is 12.55%
The return on equity (ROE) for VanEck Pharmaceutical ETF's(PPH) from its last reported annual financials is : 8.69%
The return on assets (ROA) for VanEck Pharmaceutical ETF's(PPH) from its last reported annual financials is : 2.84%
The return on invested capital (ROIC) for VanEck Pharmaceutical ETF's(PPH) from its last reported annual financials is : 0.00%
The Debt to Equity ratio for VanEck Pharmaceutical ETF's(PPH) from its last reported annual financials is : 0.00%
The dividend yield for VanEck Pharmaceutical ETF's(PPH) from its laster reported year is 1.76%
VanEck Pharmaceutical ETF's(PPH) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
